DK2947149T3 - Alphavirus-replikonpartikler til anvendelse i vaccination - Google Patents
Alphavirus-replikonpartikler til anvendelse i vaccination Download PDFInfo
- Publication number
- DK2947149T3 DK2947149T3 DK15173487.8T DK15173487T DK2947149T3 DK 2947149 T3 DK2947149 T3 DK 2947149T3 DK 15173487 T DK15173487 T DK 15173487T DK 2947149 T3 DK2947149 T3 DK 2947149T3
- Authority
- DK
- Denmark
- Prior art keywords
- alphavirus
- particles
- helper
- population
- rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (13)
1. Alphavirus-replikonpartikel til anvendelse i vaccination, immunterapi eller som en immunmodulerende faktor hos et individ, hvor alphavirus-replikonpartiklen, der er et isoleret RNA-molekyle, omfatter: a) en alphavirus 5’ replikationsgenkendelsessekvens, hvor mindst ét initieringscodon er fjernet fra 5’-replikationsgenkendelsessekvensen; b) en nukleotidsekvens, der koder for et alphavirus-strukturprotein; og c) en alphavirus-3’-replikationsgenkendelsessekvens, forudsat at RNA’et ikke indeholder en promotor, der styrer transskription af nukleotidsekvensen af (b), og hvor alphavirus-5'- og 3’-replikationsgenkendelsessekvenseme af (a) og (c) styrer replikation af hele RNA-molekylet i nærvær af et alphavirus-ikke-strukturprotein.
2. Population af alphavirus-replikonpartikler til anvendelse i vaccination, immunterapi eller som en immunmodulerende faktor, hvor populationen af alphavirus-replikonpartikler omfatter et undersæt af partikler som defineret i krav 1, hvor populationen ikke indeholder nogen detekterbare replikationskompetente alphavirus-viruspartikler pr. 108 alphavirus-replikonpartikler, bestemt ved passage på permissive celler i kultur.
3. Population af alphavirus-replikonpartikler til anvendelse i vaccination, immunterapi eller som en immunmodulerende faktor, hvor populationen af alphavirus-replikonpartikler omfatter et undersæt af partikler som defineret i krav 1, hvor populationen ikke indeholder nogen detekterbare replikationskompetente alphaviruspartikler pr. 108 alphavirus-replikonpartikler, bestemt ved passage på permissive celler i kultur, hvor alphavirus-replikonpartikleme omfatter én eller flere svækkende mutationer i enten et alphavirus-strukturprotein eller et alphavirus-ikke-strukturprotein eller både et alphavirus-strukturprotein og et alphavirus-ikke-strukturprotein.
4. Alphavirus-replikonpartikel til anvendelse ifølge krav 1 eller population af alphavirus-replikonpartikler til anvendelse ifølge krav 2 eller 3, hvor responset på vaccinationen, immunterapien eller en immunmodulerende faktor er humoralt og/eller cellulært.
5. Alphavirus-replikonpartikel til anvendelse ifølge enten krav 1 eller 4 eller population af alphavirus-replikonpartikler til anvendelse ifølge krav 2 til 4, hvor vaccination er mod et virus eller et viralt protein eller en bakterie eller et bakterielt protein.
6. Alphavirus-replikonpartikel til anvendelse ifølge enten krav 1 eller 4 eller population af alphavirus-replikonpartikler til anvendelse ifølge et hvilket som helst af kravene 2 til 4, hvor immunterapien er cancerimmunterapi.
7. Alphavirus-replikonpartikel til anvendelse ifølge enten krav 1 eller 4 eller population af alphavirus-replikonpartikler til anvendelse ifølge et hvilket som helst af kravene 2 til 4, hvor partiklerne eller populationen af partikler er alphavirus-replikonpartikeladjuvanser eller andre vaccinationsmåder.
8. Alphavirus-replikonpartikel til anvendelse ifølge et hvilket som helst af kravene 1 eller 4 til 7 eller population af alphavirus-replikonpartikler til anvendelse ifølge et hvilket som helst af kravene 2 til 7, hvor partiklerne eller populationen af partikler indgår i en celle/celler.
9. Alphavirus-replikonpartikel til anvendelse ifølge et hvilket som helst af kravene 1 eller 4 til 7 eller population af alphavirus-replikonpartikler til anvendelse ifølge et hvilket som helst af kravene 2 til 7, hvor partiklerne eller populationen af partikler indgår i en vektor.
10. Alphavirus-replikonpartikel eller population af alphavirus-replikonpartikler til anvendelse ifølge krav 9, hvor vektoren er inkorporeret i en celle.
11. Alphavirus-replikonpartikel til anvendelse ifølge et hvilket som helst af kravene 1 eller 4 til 7 eller population af alphavirus-replikonpartikler ifølge anvendelsen ifølge et hvilket som helst af kravene 2 til 7, hvor partiklen eller populationen af partikler indgår i et nukleinsyrekonstrukt.
12. Alphavirus-replikonpartikel eller population af alphavirus-replikonpartikler til anvendelse ifølge et hvilket som helst foregående krav, hvor individet er et varmblodet dyr.
13. Alphavirus-replikonpartikel eller population af alphavirus-replikonpartikler til anvendelse ifølge krav 12, hvor dyret er udvalgt fra gruppen, der omfatter menneske, ikke-human primat, hest, ko, kat, hund, gris, rotte eller mus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93663707P | 2007-06-21 | 2007-06-21 | |
EP08825920.5A EP2183368B1 (en) | 2007-06-21 | 2008-06-20 | Promoterless cassettes for expression of alphavirus structural proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2947149T3 true DK2947149T3 (da) | 2018-06-06 |
Family
ID=40156867
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08825920.5T DK2183368T3 (da) | 2007-06-21 | 2008-06-20 | Promoterfrie kassetter til ekspression af alphavirusstrukturproteiner |
DK15173487.8T DK2947149T3 (da) | 2007-06-21 | 2008-06-20 | Alphavirus-replikonpartikler til anvendelse i vaccination |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08825920.5T DK2183368T3 (da) | 2007-06-21 | 2008-06-20 | Promoterfrie kassetter til ekspression af alphavirusstrukturproteiner |
Country Status (14)
Country | Link |
---|---|
US (2) | US8460913B2 (da) |
EP (2) | EP2183368B1 (da) |
JP (3) | JP5602624B2 (da) |
CN (1) | CN101802199B (da) |
AU (1) | AU2008266807B2 (da) |
CA (1) | CA2689588C (da) |
DK (2) | DK2183368T3 (da) |
ES (2) | ES2588906T3 (da) |
HK (1) | HK1217216A1 (da) |
IL (1) | IL202720A (da) |
NZ (1) | NZ582495A (da) |
PL (2) | PL2183368T3 (da) |
WO (1) | WO2008156829A2 (da) |
ZA (1) | ZA200909080B (da) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008266807B2 (en) * | 2007-06-21 | 2012-08-16 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
US8680258B2 (en) | 2008-12-01 | 2014-03-25 | Alphavax, Inc. | Use of microRNAs to control virus helper nucleic acids |
AU2010234362B2 (en) | 2009-04-08 | 2015-11-26 | Alphavax, Inc. | Alphavirus replicon particles expressing TRP2 |
BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
ES2770335T3 (es) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | Administración de ARN para desencadenar múltiples vías inmunológicas |
EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
AU2011295935B2 (en) | 2010-08-31 | 2016-02-11 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding RNA |
KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
BE1023557B1 (fr) | 2014-02-10 | 2017-05-03 | Univercells Sa | Systeme, appareil et procede pour la production de biomolecules |
AU2017207744A1 (en) | 2016-01-11 | 2018-07-26 | Verndari, Inc. | Microneedle compositions and methods of using same |
WO2017162265A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
WO2017162266A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
EP3443107A1 (en) | 2016-04-13 | 2019-02-20 | Synthetic Genomics, Inc. | Recombinant arterivirus replicon systems and uses thereof |
BR112019007433A2 (pt) | 2016-10-17 | 2019-07-02 | Synthetic Genomics Inc | sistemas de replicon de vírus recombinante e usos dos mesmos |
AU2017372731B2 (en) * | 2016-12-05 | 2024-05-23 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
TW202333779A (zh) | 2017-05-08 | 2023-09-01 | 美商磨石生物公司 | 阿爾法病毒新抗原載體 |
CA3074919A1 (en) * | 2017-09-13 | 2019-03-21 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing a t cell receptor or an artificial t cell receptor |
AU2018333503A1 (en) * | 2017-09-13 | 2020-02-27 | BioNTech SE | RNA replicon for reprogramming somatic cells |
JP7472019B2 (ja) | 2017-11-06 | 2024-04-22 | インターベット インターナショナル ベー. フェー. | 狂犬病ウイルスワクチン |
WO2019110213A1 (en) | 2017-12-08 | 2019-06-13 | Intervet International B.V. | Feline calicivirus vaccine |
EP3706788A1 (en) | 2017-11-06 | 2020-09-16 | Intervet International B.V. | Feline leukemia virus vaccine |
US11229699B2 (en) | 2017-11-06 | 2022-01-25 | Intervet Inc. | Feline calicivirus vaccine |
AU2018358077A1 (en) | 2017-11-06 | 2020-05-14 | Intervet International B.V. | Feline leukemia virus vaccine |
US20200323975A1 (en) | 2017-12-04 | 2020-10-15 | Intervet Inc. | Vaccination with replicon particles and oil adjuvant |
US11883476B2 (en) | 2017-12-04 | 2024-01-30 | Intervet Inc. | Canine lyme disease vaccine |
CA3080087A1 (en) | 2017-12-15 | 2019-06-20 | Intervet International B.V. | Multivalent feline vaccine |
BR112020012049A2 (pt) | 2017-12-18 | 2020-11-24 | Intervet International B.V. | vacina contra vírus da influenza a suína |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
EP3740245A4 (en) | 2018-01-19 | 2022-01-05 | Janssen Pharmaceuticals, Inc. | INDUCTION AND ENHANCEMENT OF IMMUNE RESPONSES USING RECOMBINATION REPLICON SYSTEMS |
EP3897710A1 (en) | 2018-12-20 | 2021-10-27 | Intervet International B.V. | Prime-boost vaccination regimen |
BR122024002387A2 (pt) | 2019-05-30 | 2024-03-12 | Gritstone Bio, Inc. | Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral |
EP4149532A1 (en) | 2020-05-11 | 2023-03-22 | Intervet International B.V. | Feline severe acute respiratory syndrome coronavirus 2 vaccine |
CN115768785A (zh) | 2020-06-19 | 2023-03-07 | 英特维特国际股份有限公司 | 包含含有编码病毒的不同神经氨酸酶抗原的第一、第二和第三核酸序列的核酸构建体的甲型猪流感病毒疫苗 |
JP2023530135A (ja) | 2020-06-19 | 2023-07-13 | インターベット インターナショナル ベー. フェー. | 特定のウイルス系統の抗原をエンコードする核酸構築物を含むブタインフルエンザaウイルスワクチン |
JP2023530133A (ja) | 2020-06-19 | 2023-07-13 | インターベット インターナショナル ベー. フェー. | 遺伝子の特定の順序を有する核酸構築物を含むブタインフルエンザaウイルスワクチン |
CN115697398A (zh) | 2020-06-19 | 2023-02-03 | 英特维特国际股份有限公司 | 包含两种不同rna复制子颗粒的甲型猪流感病毒疫苗 |
WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
BR112023004123A2 (pt) | 2020-09-07 | 2023-04-04 | Intervet Int Bv | Vacina de haste da ha para alvos positivos de anticorpos de ha |
AU2021378483A1 (en) | 2020-11-12 | 2023-06-08 | Intervet International B.V. | Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof |
WO2023072805A1 (en) | 2021-10-25 | 2023-05-04 | Intervet International B.V. | A vaccine for the protection of piglets against swine influenza a virus infection |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
NZ225583A (en) | 1987-08-06 | 1991-07-26 | Merck & Co Inc | Process for purifying hepatitis a virions (hav) |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
US6770283B1 (en) | 1990-12-13 | 2004-08-03 | Bioption Ab | DNA expression systems based on alphaviruses |
WO1994017813A1 (en) | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
US20020102273A1 (en) | 1995-08-08 | 2002-08-01 | Robert B. Grieve | Use of alphavirus expression vectors to produce parasite anitgens |
RU2057377C1 (ru) | 1993-08-23 | 1996-03-27 | Уральский электрохимический комбинат | Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов |
EP0716148B1 (en) | 1993-09-15 | 2004-01-02 | Chiron Corporation | Recombinant alphavirus vectors |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
FR2723849B1 (fr) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US5639650A (en) | 1995-05-23 | 1997-06-17 | The University Of North Carolina At Chapel Hill | cDNA clone for South African Arbovirus No. 86 |
US6197879B1 (en) * | 1995-10-31 | 2001-03-06 | Henkel Corporation | Methods of preparing inorganic pigment dispersions |
US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
AU2809897A (en) | 1996-04-23 | 1997-11-12 | Wistar Institute Of Anatomy And Biology, The | Novel human cytomegalovirus dna constructs and uses therefor |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
JP2000514290A (ja) | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
JP2965908B2 (ja) | 1996-07-05 | 1999-10-18 | 株式会社精工技研 | 調温液体シール手段を備える光ディスク成形用金型装置 |
US5827658A (en) | 1996-08-09 | 1998-10-27 | The United States Of America As Reprsented By The Department Of Health And Human Services | Isolation of amplified genes via cDNA subtractive hybridization |
US5726022A (en) | 1996-11-18 | 1998-03-10 | Lifespan Biosciences, Inc. | Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences |
BR9713368A (pt) | 1996-11-20 | 2001-09-18 | Introgen Therapeutics Inc | Processo melhorado para a produção e a purificação de vetores adenovirais |
FR2757169B1 (fr) | 1996-12-13 | 1999-03-05 | Inst Nat Sante Rech Med | Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin |
US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
US5958738A (en) | 1997-03-24 | 1999-09-28 | Roche Diagnostics Corporation | Procedure for subtractive hybridization and difference analysis |
US6261570B1 (en) | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
GB9716611D0 (en) | 1997-08-07 | 1997-10-08 | Cantab Pharmaceuticals Res Ltd | Virus preparations and methods |
AUPO856097A0 (en) | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
US6197502B1 (en) | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
FI106618B (fi) | 1998-03-30 | 2001-03-15 | Sandvik Tamrock Oy | Sovitelma painenestekäyttöisen iskulaitteen, kuten esimerkiksi rikotuslaitteen yhteydessä |
US6844188B1 (en) | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
WO1999051263A2 (en) | 1998-04-08 | 1999-10-14 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
US7267823B2 (en) | 1998-06-29 | 2007-09-11 | United States Of America As Represented By The Secretary Of The Army | Ebola peptides and immunogenic compositions containing same |
AU767551B2 (en) | 1998-06-29 | 2003-11-13 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
CA2337966A1 (en) | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases | Vaccine against staphylococcus intoxication |
CA2336587A1 (en) | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases | Botulinum neurotoxin vaccine |
US6770479B1 (en) | 1998-07-10 | 2004-08-03 | The United States Of America As Represented By The Secretary Of The Army | Anthrax vaccine |
CA2345440A1 (en) | 1998-10-05 | 2000-04-13 | Charles A. Nicolette | Genes differentially expressed in cancer cells to design cancer vaccines |
US6242259B1 (en) | 1998-12-31 | 2001-06-05 | Chiron Corporation | Compositions and methods for packing of alphavirus vectors |
EP2206785A1 (en) | 1998-12-31 | 2010-07-14 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US6329201B1 (en) | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
ATE463578T1 (de) | 1999-04-14 | 2010-04-15 | Novartis Vaccines & Diagnostic | Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren- systeme |
ATE412763T1 (de) | 1999-08-31 | 2008-11-15 | Univ North Carolina | Antikörper-abhängige vergrösserung der alphavirus-infektvität |
JP2003511037A (ja) * | 1999-10-01 | 2003-03-25 | ジェノボ, インコーポレイテッド | AAVrep/cap遺伝子を含むアデノウイルスを使用する組換えAAVの産生 |
US7115391B1 (en) * | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
DK1285080T3 (da) | 2000-05-31 | 2008-12-01 | Novartis Vaccines & Diagnostic | Fremgangsmåde til oprensning af alphavirusreplikonpartikler |
AU2001273313A1 (en) | 2000-07-07 | 2002-01-21 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified hiv genes for use as vaccines |
US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
EP1305518B1 (en) | 2000-07-28 | 2004-06-16 | Visteon Global Technologies, Inc. | An air intake arrangement for an internal combustion engine |
AU9322201A (en) | 2000-08-29 | 2002-03-13 | American Cyanamid Co | Packaging of positive-strand rna virus replicon particles |
AU2001290642A1 (en) | 2000-09-07 | 2002-03-22 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
DE10049587A1 (de) | 2000-10-06 | 2002-05-02 | Icon Genetics Ag | Vektorsystem für Pflanzen |
DE10061150A1 (de) | 2000-12-08 | 2002-06-13 | Icon Genetics Ag | Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen |
US6800289B2 (en) | 2000-12-21 | 2004-10-05 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Strain of the western equine encephalitis virus |
AU2002305914A1 (en) | 2001-01-12 | 2002-10-21 | Chiron Corporation | Nucleic acid mucosal immunization |
DE10121283B4 (de) | 2001-04-30 | 2011-08-11 | Icon Genetics GmbH, 80333 | Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen |
AU2002303330B2 (en) | 2001-05-31 | 2008-07-24 | Novartis Vaccines And Diagnostics, Inc. | Chimeric alphavirus replicon particles |
US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
DE10143237A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente) |
DE10143238A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente |
JP4790984B2 (ja) * | 2001-09-06 | 2011-10-12 | アルファヴァックス,インコーポレイテッド | アルファウイルスレプリコンベクター系 |
AU2003222068A1 (en) | 2002-03-25 | 2003-10-13 | University Of North Carolina At Chapel Hill | Improved methods for achieving expression from alphavirus vectors |
JP3857195B2 (ja) | 2002-07-09 | 2006-12-13 | 株式会社東芝 | 距離継電装置 |
US20050031592A1 (en) | 2002-11-13 | 2005-02-10 | Doolan Denise L. | Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines |
DK2290054T3 (da) | 2002-12-13 | 2017-07-03 | Alphavax Inc | Alfavirus-partikler og fremgangsmåder til fremstilling deraf |
ES2618309T3 (es) | 2002-12-13 | 2017-06-21 | Alphavax, Inc. | Partículas de replicón de alfavirus multi-antigénico y métodos |
KR101454842B1 (ko) | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
US20060099587A1 (en) | 2003-06-20 | 2006-05-11 | Johnston Robert E | Alphavirus vectors having attentuated virion structural proteins |
US7419674B2 (en) | 2003-07-11 | 2008-09-02 | Alpha Vax, Inc. | Alpha virus-based cytomegalovirus vaccines |
EP1687033A4 (en) | 2003-11-12 | 2008-06-11 | Us Navy | STRENGTHENING IMMUNE RESPONSE INDUCED BY A VACCINE AND HETEROLOGOUS AMPLIFICATION PROTECTION WITH ALPHAVIRUS REPLICON VACCINES |
US7078087B2 (en) * | 2003-12-31 | 2006-07-18 | Kimberly-Clark Worldwide, Inc. | Wipes with an edge treatment along a leading edge portion |
CA2567254C (en) | 2004-05-18 | 2012-03-13 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
WO2006085983A2 (en) | 2004-07-09 | 2006-08-17 | University Of North Carolina At Chapel Hill | Viral adjuvants |
WO2007046839A2 (en) | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
EP2061508B1 (en) | 2006-09-12 | 2014-10-15 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
AU2008266807B2 (en) * | 2007-06-21 | 2012-08-16 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
KR101668849B1 (ko) * | 2008-01-24 | 2016-10-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 |
-
2008
- 2008-06-20 AU AU2008266807A patent/AU2008266807B2/en active Active
- 2008-06-20 US US12/665,497 patent/US8460913B2/en active Active
- 2008-06-20 WO PCT/US2008/007701 patent/WO2008156829A2/en active Search and Examination
- 2008-06-20 CN CN2008801036605A patent/CN101802199B/zh active Active
- 2008-06-20 ES ES08825920.5T patent/ES2588906T3/es active Active
- 2008-06-20 PL PL08825920.5T patent/PL2183368T3/pl unknown
- 2008-06-20 DK DK08825920.5T patent/DK2183368T3/da active
- 2008-06-20 EP EP08825920.5A patent/EP2183368B1/en active Active
- 2008-06-20 CA CA2689588A patent/CA2689588C/en active Active
- 2008-06-20 DK DK15173487.8T patent/DK2947149T3/da active
- 2008-06-20 US US12/143,320 patent/US7850977B2/en active Active
- 2008-06-20 JP JP2010513254A patent/JP5602624B2/ja active Active
- 2008-06-20 ES ES15173487.8T patent/ES2670813T3/es active Active
- 2008-06-20 NZ NZ582495A patent/NZ582495A/en unknown
- 2008-06-20 EP EP15173487.8A patent/EP2947149B1/en active Active
- 2008-06-20 PL PL15173487T patent/PL2947149T3/pl unknown
-
2009
- 2009-12-14 IL IL202720A patent/IL202720A/en active IP Right Grant
- 2009-12-18 ZA ZA200909080A patent/ZA200909080B/xx unknown
-
2014
- 2014-08-20 JP JP2014167257A patent/JP5995926B2/ja active Active
-
2016
- 2016-05-09 HK HK16105221.2A patent/HK1217216A1/zh unknown
- 2016-08-23 JP JP2016162382A patent/JP2016198114A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ZA200909080B (en) | 2010-09-29 |
PL2183368T3 (pl) | 2016-12-30 |
EP2183368A4 (en) | 2011-04-13 |
US8460913B2 (en) | 2013-06-11 |
EP2183368A2 (en) | 2010-05-12 |
AU2008266807B2 (en) | 2012-08-16 |
ES2588906T3 (es) | 2016-11-07 |
CN101802199B (zh) | 2012-08-22 |
HK1217216A1 (zh) | 2016-12-30 |
JP2010530245A (ja) | 2010-09-09 |
US7850977B2 (en) | 2010-12-14 |
EP2183368B1 (en) | 2016-08-10 |
WO2008156829A3 (en) | 2009-03-12 |
JP5995926B2 (ja) | 2016-09-21 |
JP2014230544A (ja) | 2014-12-11 |
ES2670813T3 (es) | 2018-06-01 |
AU2008266807A1 (en) | 2008-12-24 |
IL202720A0 (en) | 2011-08-01 |
EP2947149B1 (en) | 2018-02-28 |
WO2008156829A2 (en) | 2008-12-24 |
CN101802199A (zh) | 2010-08-11 |
PL2947149T3 (pl) | 2018-09-28 |
IL202720A (en) | 2013-10-31 |
CA2689588A1 (en) | 2008-12-24 |
JP2016198114A (ja) | 2016-12-01 |
US20090075384A1 (en) | 2009-03-19 |
DK2183368T3 (da) | 2016-09-05 |
US20100183665A1 (en) | 2010-07-22 |
CA2689588C (en) | 2016-08-23 |
JP5602624B2 (ja) | 2014-10-08 |
NZ582495A (en) | 2012-05-25 |
EP2947149A1 (en) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2947149T3 (da) | Alphavirus-replikonpartikler til anvendelse i vaccination | |
US10570416B2 (en) | TC-83-derived alphavirus vectors, particles and methods | |
JP5572144B2 (ja) | 改良されたアルファウイルスレプリコンおよびヘルパー構築物 | |
US8961995B2 (en) | Methods and compositions for alphavirus replicons | |
US20140308312A1 (en) | Use of micrornas to control virus helper nucleic acids |